Results 71 to 80 of about 21,074 (263)

Identification and Discrimination of Sulfated and Unsulfated Gut‐Hormone Biomarkers in Human Serum by Nanopore

Small, EarlyView.
This study discriminates between sulfated and unsulfated cholecystokinin‐8 gut‐hormone forms at single‐molecule‐level resolution. Using an aerolysin nanopore embedded in a hybrid lipid‐polymer membrane, the system produces distinct electrical signatures enabling highly sensitive detection, even in 20% human serum.
Luca Iesu, Laurent Bacri, Juan Pelta, Benjamin Cressiot   +3 more
wiley   +1 more source

Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culprit obstructive and multivessel non obstructive-coronary-stenosis

Diabetology & Metabolic Syndrome, 2018
Background No proper data on prognosis and management of type-2 diabetic ST elevation myocardial infarction (STEMI) patients with culprit obstructive lesion and multivessel non obstructive coronary stenosis (Mv-NOCS) exist.
Raffaele Marfella, Celestino Sardu, Maria Luisa Balestrieri, Mario Siniscalchi, Fabio Minicucci, Giuseppe Signoriello, Paolo Calabrò, Ciro Mauro, Gorizio Pieretti, Antonino Coppola, Gianfranco Nicoletti, Maria Rosaria Rizzo, Giuseppe Paolisso, Michelangela Barbieri   +13 more
doaj   +1 more source

Dipeptidyl Peptidase‐4 Inhibitor Use and Risk of Pemphigus Vulgaris and Foliaceus: A Retrospective Cohort Study Using Databases of the Korea National Health Insurance Claims and the National Health Screening Examination

The Journal of Dermatology, EarlyView.
ABSTRACT Although population‐based studies have reported an increased risk of bullous pemphigoid and pemphigus associated with dipeptidyl peptidase‐4 (DPP‐4) inhibitors, there is limited, well‐designed epidemiological evidence for pemphigus vulgaris (PV), which has only been supported by case reports thus far.
Jaein Lee, Jae Hyun Bae, Seokyung Hahn
wiley   +1 more source

Timing and duration of glucagon‐like peptide‐1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy

Acta Ophthalmologica, EarlyView.
Abstract Purpose To investigate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and nonarteritic anterior ischaemic optic neuropathy (NAION) in type 2 diabetes, examining treatment recency and cumulative duration. Methods This nationwide registry‐based nested case–control study utilizedz Danish health registries (1996 ...
Siar Niazi, Filip Gnesin, Baker Nawfal Jawad, Zia Niazi, Puriya Daniel Wuertz Yazdanfard, Anne P. Toft‐Petersen, Kathrine Kold Sørensen, Amani Meaidi, Yousif Subhi, Christian Torp‐Pedersen   +9 more
wiley   +1 more source

Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective

Journal of Nutrition and Metabolism, 2012
In recent years the incretin therapies have provided a new treatment option for patients with type 2 diabetes mellitus (T2DM). The incretin therapies focus on the increasing levels of the two incretin hormones, glucagon-like peptide 1 (GLP-1) and glucose-
Dominique Xavier Brown, Marc Evans
doaj   +1 more source

Review Article: Fibrosis Reversal in Metabolic Dysfunction‐Associated Steatohepatitis—The Promise of Emerging Therapeutics

Alimentary Pharmacology &Therapeutics, EarlyView.
Metabolic dysfunction‐associated steatohepatitis is the second commonest US indication for liver transplantation but remains largely undiagnosed and untreated. Fibrosis stage is the strongest predictor of major adverse liver outcomes, with decompensation rates and transplant‐free survival diverging sharply between F3 and F4, while cardiovascular ...
Malek Ayoub, Tsubasa Tsutsumi, Mary E. Rinella   +2 more
wiley   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Glucagon‐like peptide‐1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions

British Journal of Pharmacology, EarlyView.
Abstract Gastric inhibitory polypeptide (GIP)/Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are increasingly prescribed for the management of obesity and type 2 diabetes, yet research pertinent to their effects on muscle health is limited. Considering the central role of muscle strength as a sarcopenia component, this article summarizes emerging ...
Konstantinos Prokopidis
wiley   +1 more source

Incretin levels 1 month after laparoscopic single anastomosis gastric bypass surgery in non-morbid obese type 2 diabetes patients

Asian Journal of Surgery, 2014
Purpose: Bariatric surgery is an efficient procedure for the remission of type 2 diabetes (T2DM) from morbid obesity. However, in Asian countries, the mean body mass index (BMI) of T2DM patients is about 25 kg/m2.
Myung Jin Kim, Hyeong Kyu Park, Dong Won Byun, Kyo Il Suh, Kyung Yul Hur   +4 more
doaj   +1 more source

Pleiotropic effects of incretins

Indian Journal of Endocrinology and Metabolism, 2012
Drugs that augment the incretin system [glucagon like peptide (GLP) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors] represent a novel class of anti-hyperglycemic agents that have shown to improve the health and survival of beta-cells (improvement in postprandial hyperglycemia) and suppress glucagon (improvement in fasting hyperglycemia).
openaire   +3 more sources